依折麦布的研究进展(3)
[6] HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant： trial design， pre-specified muscle and liver outcomes， and reasons for stopping study treatment[J]. Eur Heart J，2013，34(17)：1279-1291.[7] Carcia-calvo M ......
您现在查看是摘要页，全文长 2566 字符。